The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work. Continue reading The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up originally appeared on DailyFinance on Wed, 09 Feb 2011 20:00:00. Filed Under: Health Care , Genzyme Corporation , GlaxoSmithKline , Novartis , Amgen , Eli Lilly Permalink | Tweet this! | Comments
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here